CXCL12 G801A polymorphism is associated with an increased risk of benign salivary gland tumors in the Chinese population

The chemokine CXCL12 and its receptor CXCR4 have been found to be important in tumor progression. A single-nucleotide polymorphism of CXCL12 G801A has been described and investigated in human immunodeficiency virus-1 (HIV-1) infection and in the susceptibility to several cancers. Here, we investigated the association between the CXCL12 G801A polymorphism and susceptibility to benign and malignant salivary gland tumors (SGTs) by polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) in 102 Chinese SGT patients and 101 healthy controls. The frequencies of the AG (P = 0.001; odds ratio (OR), 3.764) and AA (P = 0.004; OR, 6.852) genotypes of CXCL12 were significantly higher in patients with benign SGTs than in the healthy controls. The frequency of the A allele of CXCL12 was also significantly higher in benign SGTs (P = 0.00; OR, 1.395) compared with the healthy controls. However, the AG (P = 0.171; OR, 3.163) and AA (P = 0.854; OR, 0.667) genotypes did not increase the risk of malignant SGTs significantly. The frequency of the CXCL12 A allele was also not found to be higher in malignant SGTs (P = 0.267; OR, 1.917) compared with the controls. Taken together, our results suggested that the CXCL12 G801A polymorphism is associated with an increased risk of benign SGTs, but not malignant SGTs, in the Chinese population.